Vimarsana
Biggest News Aggregation in the World

Support Weaning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Support Weaning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Support Weaning Today - Breaking & Trending Today

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 - Vimarsana News

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

Published: May 1, 2024

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET – – Findings from the STARS...

Source: marketscreener.com
Related Topics:
United StatesMichael ShetzlineIronwood Pharmaceuticals NasdaqExchange CommissionA National Survey AnalysisIronwood PharmaceuticalsIronwood Pharmaceuticals IncCenter TrialDrug AdministrationDisease WeekApraglutide Once WeeklyShort Bowel SyndromeIntestinal FailureGlobal PhasePlacebo Controlled TrialBowel MorphologyMotility AssessedShort Bowel Syndrome Intestinal FailureColon In Continuity TreatedSupport WeaningClinical BenefitImproved Patient Reported OutcomesLong Acting Glucagon LikeAnalog ApraglutideIncreased Oral Intake
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week 2024 - Vimarsana News

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week 2024

Published: May 1, 2024

01.05.2024 - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a ... Seite 1

Source: wallstreet-online.de
Related Topics:
Michael ShetzlineDrug AdministrationCenter TrialIronwood PharmaceuticalsApraglutide Once WeeklyShort Bowel SyndromeIntestinal FailureGlobal PhasePlacebo Controlled TrialBowel MorphologyMotility AssessedShort Bowel Syndrome Intestinal FailureColon In Continuity TreatedSupport WeaningClinical BenefitImproved Patient Reported OutcomesLong Acting Glucagon LikeAnalog ApraglutideIncreased Oral IntakeImproved EnergyCarbohydrate AbsorptionGastric EmptyingHealthy IndividualsSingle Center TrialBowel Syndrome